8-K: Polomar Health Services Amends Patent License Agreement with Pinata Holdings

Polomar Health Services has amended its patent license agreement with Pinata Holdings, securing a perpetual, non-exclusive worldwide license for key pharmaceutical ingredients.

Summary

• Polomar Health Services, formerly Trustfeed Corp, has entered into an amended and restated Know-How and Patent License Agreement with Pinata Holdings.
• This agreement supersedes the original agreement from June 29, 2024, and grants Polomar a worldwide, non-exclusive, and non-transferable license to use Pinata's intellectual property.
• The license covers the proprietary delivery of products containing metformin, sumatriptan, semaglutide, liraglutide, and sildenafil.
• Polomar will pay Pinata a royalty ranging from 10% to 20% of net sales from products utilizing the licensed IP.
• The agreement has a perpetual term but can be terminated by either party for material breach or with 180 days' notice.
• Polomar's subsidiary, Polomar Specialty Pharmacy, is also a party to the agreement and will utilize the IP rights.
• Pinata is an affiliate of CWR 1, LLC, Polomar's majority shareholder, through common ownership.

Sentiment

Score: 7

Explanation: The document outlines a positive development for Polomar, securing a long-term license for key pharmaceutical ingredients. However, the non-exclusive nature of the license and the royalty payments introduce some uncertainty.

Positives

• The agreement provides Polomar with a perpetual license, ensuring long-term access to the intellectual property.
• The license is worldwide, allowing Polomar to expand its market reach.
• The agreement allows for sub-licensing, providing flexibility for Polomar's business strategy.
• The inclusion of Polomar Specialty Pharmacy as a party ensures the subsidiary can directly utilize the licensed IP.
• The agreement includes a clause for negotiating revised royalties upon expiration of all valid claims for each product.

Negatives

• The license is non-exclusive, meaning Pinata can license the same IP to other companies.
• The royalty payments, ranging from 10% to 20%, could impact Polomar's profitability.
• The agreement can be terminated with 180 days' notice, creating some uncertainty.
• The agreement is non-transferable, limiting Polomar's options in case of a merger or acquisition.

Risks

• There is a risk that Pinata may not be granted the pending patents under the IP Rights.
• Polomar's ability to effectively utilize the licensed IP to increase customer value and financial returns is not guaranteed.
• There is a risk that the pending merger between Polomar and Polomar Specialty Pharmacy will not be consummated.
• The company faces risks related to integrating the IP Rights into the existing Polomar business and realizing the anticipated benefits of the license.

Future Outlook

The company intends to utilize the licensed IP rights in products manufactured and distributed by its wholly owned subsidiary Polomar Specialty Pharmacy, LLC. The company also has a pending merger with Polomar Specialty Pharmacy.

Management Comments

• The company believes forward-looking statements are based upon reasonable assumptions, but such statements involve known and unknown risks, uncertainties, and other factors.

Industry Context

This agreement is relevant to the pharmaceutical industry, particularly in the area of drug delivery and intellectual property licensing. The specific ingredients covered by the license are used in treatments for diabetes, migraines, and weight management, which are significant markets.

Comparison to Industry Standards

• Licensing agreements in the pharmaceutical industry are common, with royalty rates varying based on the exclusivity, market potential, and stage of development of the licensed technology.
• A 10-20% royalty rate is within the typical range for pharmaceutical licenses, but the specific rate depends on the specific terms of the agreement.
• Perpetual licenses are less common than term-based licenses, suggesting a strong commitment from Pinata to Polomar.
• Non-exclusive licenses are more common than exclusive licenses, allowing the licensor to generate revenue from multiple sources.

Related Party Transactions

• Pinata is an affiliate of CWR 1, LLC, Polomar's majority shareholder, through common ownership.

Stakeholder Impact

• Shareholders may view this agreement positively as it secures access to valuable intellectual property.
• Employees of Polomar and Polomar Specialty Pharmacy will be involved in the development and manufacturing of products utilizing the licensed IP.
• Customers may benefit from new and improved products developed using the licensed technology.
• Suppliers may see increased demand for materials used in the production of these products.

Next Steps

• Polomar will integrate the licensed IP into its product development and manufacturing processes.
• Polomar will begin paying royalties to Pinata based on net sales of products utilizing the licensed IP.
• Polomar will continue to work towards the completion of the pending merger with Polomar Specialty Pharmacy.

Key Dates

Keywords

patent license, intellectual property, pharmaceuticals, metformin, sumatriptan, semaglutide, liraglutide, sildenafil, royalty, Polomar Health Services, Pinata Holdings